Protective role of the ACE2/Ang-(19) axis in cardiovascular remodeling

International Journal of Hypertension

Volumn 2012, Issue , 2012, Pages

  Ocaranza, María Paz ^a   Jalil, Jorge E ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ANGIOPOIETIN 3; ANGIOPOIETIN 4; ANGIOPOIETIN 5; ANGIOPOIETIN 6; ANGIOPOIETIN 7; ANGIOPOIETIN 8; ANGIOPOIETIN 9; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR; CANDESARTAN; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; G PROTEIN COUPLED RECEPTOR; LOSARTAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

BINDING AFFINITY; CARDIOVASCULAR DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; KIDNEY FAILURE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOCONSTRICTION;

EID: 84868271237     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2012/594361     Document Type: Review

References (117)

1. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo J. L., Jones D. W., Materson B. J., Oparil S., Wright J. T., Roccella E. J., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 42 6 1206 1252 2-s2.0-0347423198 10.1161/01.HYP.0000107251.49515.c2 (Pubitemid 37553153)
2. Intengan H. D., Schiffrin E. L., Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000 36 3 312 318 2-s2.0-0033822718
3. Dielis A. W. J. H., Smid M., Spronk H. M. H., Hamulyak K., Kroon A. A., Ten Cate H., De Leeuw P. W., The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension 2005 46 6 1236 1242 2-s2.0-31944445388 10.116110.1161/01.HYP.0000193538.20705.23 (Pubitemid 43189713)
4. Ferrario C. M., Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. Journal of the Renin-Angiotensin-Aldosterone System 2006 7 1 3 14 2-s2.0-33745150754 10.3317/jraas.2006.003 (Pubitemid 43891239)
5. Weir M. R., Effects of renin-angiotensin system inhibition end-organ protection: can we do better? Clinical Therapeutics 2007 29 9 1803 1824 2-s2.0-36749043046 10.1016/j.clinthera.2007.09.019 (Pubitemid 350214460)
6. Danser A. H. J., (Pro)renin receptors: are they biologically relevant? Current Opinion in Nephrology and Hypertension 2009 18 1 74 78 2-s2.0-58149216360 10.1097/MNH.0b013e3283196aaf
7. Weir M. R., Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade. Journal of Human Hypertension 2007 21 10 770 779 2-s2.0-34548847762 10.1038/sj.jhh.1002254 (Pubitemid 47450002)
8. Kearney P. M., Whelton M., Reynolds K., Muntner P., Whelton P. K., He J., Global burden of hypertension: analysis of worldwide data. The Lancet 2005 365 9455 217 223 2-s2.0-12344282783 10.1016/S0140-6736(05)17741-1 (Pubitemid 40138015)
9. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., Donovan M., Woolf B., Robison K., Jeyaseelan R., Breitbart R. E., Acton S., A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation Research 2000 87 5 E1 E9 2-s2.0-0038053724
10. Tipnis S. R., Hooper N. M., Hyde R., Karran E., Christie G., Turner A. J., A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase. Journal of Biological Chemistry 2000 275 43 33238 33243 2-s2.0-0034721906 10.1074/jbc.M002615200
11. Danilczyk U., Eriksson U., Crackower M. A., Penninger J. M., A story of two ACEs. Journal of Molecular Medicine 2003 81 4 227 234 2-s2.0-0038245144 (Pubitemid 36578921)
12. Oudit G. Y., Crackower M. A., Backx P. H., Penninger J. M., The role of ACE2 in cardiovascular physiology. Trends in Cardiovascular Medicine 2003 13 3 93 101 2-s2.0-0037383515 10.1016/S1050-1738(02)00233-5 (Pubitemid 36411803)
13. Turner A. J., Tipnis S. R., Guy J. L., Rice G. I., Hooper N. M., ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Canadian Journal of Physiology and Pharmacology 2002 80 4 346 353 2-s2.0-0036253032 10.1139/y02-021 (Pubitemid 34451252)
14. Gembardt F., Sterner-Kock A., Imboden H., Spalteholz M., Reibitz F., Schultheiss H. P., Siems W. E., Walther T., Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 2005 26 7 1270 1277 2-s2.0-20444407675 10.1016/j.peptides.2005.01.009 (Pubitemid 40798085)
15. Epelman S., Shrestha K., Troughton R. W., Francis G. S., Sen S., Klein A. L., Wilson Tang W. H., Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. Journal of Cardiac Failure 2009 15 7 565 571 2-s2.0-68849105984 10.1016/j.cardfail.2009.01. 014
16. Lambert D. W., Yarski M., Warner F. J., Thornhill P., Parkin E. T., Smith A. I., Hooper N. M., Turner A. J., Tumor necrosis factor- α convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). Journal of Biological Chemistry 2005 280 34 30113 30119 2-s2.0-24044444558 10.1074/jbc.M505111200 (Pubitemid 41216188)
17. Elased K. M., Cunha T. S., Gurley S. B., Coffman T. M., Morris M., New mass spectrometric assay for angiotensin-converting enzyme 2 activity. Hypertension 2006 47 5 1010 1017 2-s2.0-33646145519 10.1161/01.HYP.0000215588. 38536.30 (Pubitemid 44297576)
18. Rice G. I., Jones A. L., Grant P. J., Carter A. M., Turner A. J., Hooper N. M., Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 2006 48 5 914 920 2-s2.0-33750264733 10.1161/01.HYP.0000244543.91937.79 (Pubitemid 44611005)
19. Lew R. A., Warner F. J., Hanchapola I., Yarski M. A., Manohar J., Burrell L. M., Smith A. I., Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Experimental Physiology 2008 93 5 685 693 2-s2.0-42649095968 10.1113/expphysiol.2007.040352 (Pubitemid 351595050)
20. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P., Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. Journal of Biological Chemistry 2002 277 17 14838 14843 2-s2.0-18544378161 10.1074/jbc.M200581200 (Pubitemid 34952556)
21. Rice G. I., Thomas D. A., Grant P. J., Turner A. J., Hooper N. M., Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochemical Journal 2004 383 1 45 51 2-s2.0-6344246036 10.1042/BJ20040634 (Pubitemid 39389449)
22. Drummer O. H., Kourtis S., Johnson H., Formation of angiotensin II and other angiotensin peptides from des-leu 10-angiotensin I in rat lung and kidney. Biochemical Pharmacology 1988 37 22 4327 4333 2-s2.0-0023727622 (Pubitemid 18265755)
23. Singh R., Singh A. K., Leehey D. J., A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. American Journal of Physiology 2005 288 6 F1183 F1190 2-s2.0-18744376906 10.1152/ajprenal.00159.2003 (Pubitemid 40677088)
24. Kokkonen J. O., Saarinen J., Kovanen P. T., Regulation of local angiotensin II formation in the human heart in the presence of interstitial fluid: inhibition of chymase by protease inhibitors of interstitial fluid and of angiotensin-converting enzyme by ANG-(1-9) formed by heart carboxypeptidase A-like activity. Circulation 1997 95 6 1455 1463 2-s2.0-0030971415 (Pubitemid 27142803)
25. Ye M., Wysocki J., Naaz P., Salabat M. R., LaPointe M. S., Batlle D., Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004 43 5 1120 1125 2-s2.0-2342472108 10.1161/01.HYP.0000126192.27644.76 (Pubitemid 38579924)
26. Rivière G., Michaud A., Breton C., VanCamp G., Laborie C., Enache M., Lesage J., Deloof S., Corvol P., Vieau D., Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. Hypertension 2005 46 5 1169 1174 2-s2.0-27444433984 10.1161/01.HYP.0000185148.27901.fe (Pubitemid 41533021)
27. Kakoki M., McGarrah R. W., Kim H. S., Smithies O., Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proceedings of the National Academy of Sciences of the United States of America 2007 104 18 7576 7581 2-s2.0-34250654947 10.1073/pnas.0701617104 (Pubitemid 47185948)
28. Schiavone M. T., Santos R. A. S., Brosnihan K. B., Khosla M. C., Ferrario C. M., Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proceedings of the National Academy of Sciences of the United States of America 1988 85 11 4095 4098 2-s2.0-0000254274
29. Souza Dos Santos R. A., Passaglio K. T., Pesquero J. B., Bader M., Simões E Silva A. C., Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. Hypertension 2001 38 3 660 664 2-s2.0-0035459470
30. Maia L. G., Ramos M. C., Fernandes L., De Carvalho M. H.C., Campagnole-Santos M. J., Dos Santos R. A.S., marrob@dedalus.lee.ufmg.br Angiotensin-(1-7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. Journal of Cardiovascular Pharmacology 2004 43 5 685 691 10.1097/00005344-200405000-00011 (Pubitemid 38534069)
31. Santos R. A. S., Simoes e Silva A. C., Maric C., Silva D. M. R., Machado R. P., De Buhr I., Heringer-Walther S., Pinheiro S. V. B., Lopes M. T., Bader M., Mendes E. P., Lemos V. S., Campagnole-Santos M. J., Schultheiss H. P., Speth R., Walther T., Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8258 8263 2-s2.0-0037478671 10.1073/pnas.1432869100 (Pubitemid 36842532)
32. Kostenis E., Milligan G., Christopoulos A., Sanchez-Ferrer C. F., Heringer-Walther S., Sexton P. M., Gembardt F., Kellett E., Martini L., Vanderheyden P., Schultheiss H. P., Walther T., G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005 111 14 1806 1813 2-s2.0-20244388129 10.1161/01.CIR.0000160867.23556.7D (Pubitemid 40525146)
33. Sampaio W. O., Dos Santos R. A. S., Faria-Silva R., Da Mata Machado L. T., Schiffrin E. L., Touyz R. M., Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007 49 1 185 192 2-s2.0-33847018997 10.1161/01.HYP. 0000251865.35728.2f (Pubitemid 46360359)
34. Tallant E. A., Ferrario C. M., Gallagher P. E., Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. American Journal of Physiology 2005 289 4 H1560 H1566 2-s2.0-25444473110 10.1152/ajpheart.00941.2004 (Pubitemid 41368998)
35. Kaschina E., Unger T., Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Pressure 2003 12 2 70 88 2-s2.0-0037527730 10.1080/08037050310001057 (Pubitemid 36700689)
36. Horiuchi M., Akishita M., Dzau V. J., Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999 33 2 613 621 2-s2.0-0033031543 (Pubitemid 29091636)
37. Savoia C., Tabet F., Yao G., Schiffrin E. L., Touyz R. M., Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. Journal of Hypertension 2005 23 5 1037 1045 2-s2.0-18344374044 (Pubitemid 40637923)
38. Hu C., Dandapat A., Chen J., Liu Y., Hermonat P. L., Carey R. M., Mehta J. L., Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis 2008 199 2 288 294 2-s2.0-47649128227 10.1016/j.atherosclerosis.2007.11.006
39. Touyz R. M., Schiffrin E. L., Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacological Reviews 2000 52 4 639 672 2-s2.0-0033635110
40. Henrion D., Kubis N., Lévy B. I., Physiological and pathophysiological functions of the AT2 subtype receptor of angiotensin II from large arteries to the microcirculation. Hypertension 2001 38 5 1150 1157 2-s2.0-0035725997 (Pubitemid 34252821)
41. Abadir P. M., Carey R. M., Siragy H. M., Angiotensin AT2 receptors directly stimulate renal nitric oxide in Bradykinin B2-receptor-null mice. Hypertension 2003 42 4 I 600 604 2-s2.0-0141997228 10.1161/01.HYP.0000090323. 58122.5C (Pubitemid 37237360)
42. Savoia C., Ebrahimian T., He Y., Gratton J. P., Schiffrin E. L., Touyz R. M., Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. Journal of Hypertension 2006 24 12 2417 2422 2-s2.0-33750575906 10.1097/01.hjh.0000251902.85675.7e (Pubitemid 44684690)
43. Dandapat A., Hu C. P., Chen J., Liu Y., Khan J. A., Remeo F., Carey R. M., Hermonat P. L., Mehta J. L., Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque. Biochemical and Biophysical Research Communications 2008 366 4 871 877 2-s2.0-37549029151 10.1016/j.bbrc.2007.11.061
44. Brassard P., Amiri F., Schiffrin E. L., Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix metalloproteinases in resistance arteries. Hypertension 2005 46 3 598 606 2-s2.0-25444459936 10.1161/01.HYP.0000176744.15592.7d (Pubitemid 41376842)
45. Dimitropoulou C., White R. E., Fuchs L., Zhang H., Catravas J. D., Carrier G. O., Angiotensin II relaxes microvessels via the AT2 receptor and Ca2+-activated K+ (BKCa) channels. Hypertension 2001 37 2 I 301 307 2-s2.0-0035091037 (Pubitemid 32199091)
46. Horiuchi M., Hayashida W., Kambe T., Yamada T., Dzau V. J., Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. Journal of Biological Chemistry 1997 272 30 19022 19026 2-s2.0-0030789196 10.1074/jbc.272.30.19022 (Pubitemid 27318258)
47. Bedecs K., Elbaz N., Sutren M., Masson M., Susini C., Strosberg A. D., Nahmias C., Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochemical Journal 1997 325 2 449 454 2-s2.0-0030851632 (Pubitemid 27338727)
48. Erdös E. G., Jackman H. L., Brovkovych V., Tan F., Deddish P. A., Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. Journal of Molecular and Cellular Cardiology 2002 34 12 1569 1576 2-s2.0-0036903274 10.1006/jmcc.2002.2080 (Pubitemid 35454473)
49. Warner F. J., Smith A. I., Hooper N. M., Turner A. J., Angiotensin-converting enzyme-2: a molecular and cellular perspective. Cellular and Molecular Life Sciences 2004 61 21 2704 2713 2-s2.0-11144257716 10.1007/s00018-004-4240-7 (Pubitemid 40022431)
50. Johnson H., Kourtis S., Waters J., Drummer O. H., Radioimmunoassay for immunoreactive [des-Leu10]-angiotensin I. Peptides 1989 10 3 489 492 2-s2.0-0024308075
51. Ocaranza M. P., Godoy I., Jalil J. E., Varas M., Collantes P., Pinto M., Roman M., Ramirez C., Copaja M., Diaz-Araya G., Castro P., Lavandero S., Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006 48 4 572 578 2-s2.0-33750589885 10.1161/01.HYP.0000237862.94083.45 (Pubitemid 44843858)
52. Ocaranza M. P., Lavandero S., Jalil J. E., Moya J., Pinto M., Novoa U., Apablaza F., González L., Hernández C., Varas M., López R., Godoy I., Verdejo H., Chiong M., Angiotensin-(1-9) regulates cardiac hypertrophy in vivo and in vitro. Journal of Hypertension 2010 28 5 1054 1064 2-s2.0-77951293287 10.1097/HJH.0b013e328335d291
53. Drummer O. H., Kourtis S., Johnson H., Effect of chronic enalapril treatment on enzymes responsible for the catabolism of angiotensin I and formation of angiotensin II. Biochemical Pharmacology 1990 39 3 513 518 2-s2.0-0025186766 10.1016/0006-2952(90)90058-S (Pubitemid 20041920)
54. Jackman H. L., Massad M. G., Sekosan M., Tan F., Brovkovych V., Marcic B. M., Erdös E. G., Angiotensin 1-9 and 1-7 release in human heart role of cathepsin A. Hypertension 2002 39 5 976 981 2-s2.0-0036112468 10.1161/01.HYP.0000017283.67962.02 (Pubitemid 34547796)
55. Chen Z., Tan F., Erdös E. G., Deddish P. A., Hydrolysis of angiotensin peptides by human angiotensin I-converting enzyme and the resensitization of B2 kinin receptors. Hypertension 2005 46 6 1368 1373 2-s2.0-31944445995 10.1161/01.HYP.0000188905.20884.63 (Pubitemid 43189737)
56. Flores-Muñoz M., Smith N. J., Haggerty C., Milligan G., Nicklin S. A., stuart.nicklin@glasgow.ac.uk Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. Journal of Physiology 2011 589 4 939 951 10.1113/jphysiol.2010.203075
57. Galandrin S., Oligny-Longpré G., Bouvier M., The evasive nature of drug efficacy: implications for drug discovery. Trends in Pharmacological Sciences 2007 28 8 423 430 2-s2.0-34447642715 10.1016/j.tips.2007.06.005 (Pubitemid 47087968)
58. Kenakin T., Functional selectivity through protean and biased agonism: who steers the ship? Molecular Pharmacology 2007 72 6 1393 1401 2-s2.0-36348946976 10.1124/mol.107.040352 (Pubitemid 350146075)
59. Smith N. J., Bennett K. A., Milligan G., When simple agonism is not enough: emerging modalities of GPCR ligands. Molecular and Cellular Endocrinology 2011 331 2 241 247 2-s2.0-78650301416 10.1016/j.mce.2010.07.009
60. Miura S. I., Karnik S. S., Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. Journal of Hypertension 1999 17 3 397 404 2-s2.0-0032973878 10.1097/00004872-199917030- 00013 (Pubitemid 29116648)
61. Zou Y., Komuro I., Yamazaki T., Aikawa R., Kudoh S., Shiojima I., Hiroi Y., Mizuno T., Yazaki Y., Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. Journal of Biological Chemistry 1996 271 52 33592 33597 2-s2.0-0030449250 10.1074/jbc.271.52.33592 (Pubitemid 27010177)
62. Vijayan K., Szotek E. L., Martin J. L., Samarel A. M., Protein kinase C- α -induced hypertrophy of neonatal rat ventricular myocytes. American Journal of Physiology 2004 287 6 H2777 H2789 2-s2.0-9344258622 10.1152/ajpheart.00171.2004 (Pubitemid 39557152)
63. Pan J., Singh U. S., Takahashi T., Oka Y., Palm-Leis A., Herbelin B. S., Baker K. M., PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and mitogen-activated protein kinases in cardiomyocytes. Journal of Cellular Physiology 2005 202 2 536 553 2-s2.0-11144269771 10.1002/jcp.20151 (Pubitemid 40041325)
64. Crackower M. A., Sarao R., Oudit G. Y., Yagil C., Kozieradzki I., Scanga S. E., Oliveira-dos-Santos A. J., Da Costa J., Zhang L., Pei Y., Scholey J., Ferrarlo C. M., Manoukian A. S., Chappell M. C., Backx P. H., Yagil Y., Penninger J. M., Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002 417 6891 822 828 2-s2.0-0037142101 10.1038/nature00786 (Pubitemid 34670323)
65. Zhong J. C., Huang D. Y., Yang Y. M., Li Y. F., Liu G. F., Song X. H., Du K., Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats. Hypertension 2004 44 6 907 912 2-s2.0-9644258509 10.1161/01.HYP.0000146400.57221.74 (Pubitemid 39577420)
66. Tikellis C., Cooper M. E., Bialkowski K., Johnston C. I., Burns W. C., Lew R. A., Smith A. I., Thomas M. C., Developmental expression of ACE2 in the SHR kidney: a role in hypertension? Kidney International 2006 70 1 34 41 2-s2.0-33745725913 10.1038/sj.ki.5000428 (Pubitemid 44000118)
67. Hamming I., Kreutz R., Sluimer J., Renal angiotensin-converting enzyme 2 is unaltered in experimental hypertension. Journal of the American Society of Nephrology 2005 16, article THPO294-TH-PO294
68. Rentzsch B., Todiras M., Iliescu R., Popova E., Campos L. A., Oliveira M. L., Baltatu O. C., Santos R. A., Bader M., Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension 2008 52 5 967 973 2-s2.0-55949126600 10.1161/HYPERTENSIONAHA.108.114322
69. Díez-Freire C., Vázquez J., Correa De Adjounian M. F., Ferrari M. F. R., Yuan L., Silver X., Torres R., Raizada M. K., ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiological Genomics 2006 27 1 12 19 2-s2.0-33749437743 10.1152/ physiolgenomics.00312.2005 (Pubitemid 44511821)
70. Der Sarkissian S., Grobe J. L., Yuan L., Narielwala D. R., Walter G. A., Katovich M. J., Raizada M. K., Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008 51 3 712 718 2-s2.0-39749202869 10.1161/HYPERTENSIONAHA.107.100693 (Pubitemid 351301525)
71. Yamazato M., Yamazato Y., Sun C., Diez-Freire C., Raizada M. K., Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 2007 49 4 926 931 2-s2.0-34047193877 10.1161/01.HYP.0000259942.38108.20 (Pubitemid 351664196)
72. Brosnihan K. B., Li P., Ferrario C. M., Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996 27 3 523 528 2-s2.0-0029926375 (Pubitemid 26086221)
73. Osei S. Y., Ahima R. S., Minkes R. K., Weaver J. P., Khosla M. C., Kadowitz P. J., Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. European Journal of Pharmacology 1993 234 1 35 42 2-s2.0-0027497895 10.1016/0014-2999(93)90703-K (Pubitemid 23093402)
74. Porsti I., Bara A. T., Busse R., Hecker M., Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. British Journal of Pharmacology 1994 111 3 652 654 2-s2.0-0028275331 (Pubitemid 24151646)
75. Zhong J., Basu R., Guo D., Chow F. L., Byrns S., Schuster M., Loibner H., Wang X. H., Penninger J. M., Kassiri Z., Oudit G. Y., Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010 122 7 717 728 2-s2.0-77955981900 10.1161/CIRCULATIONAHA.110.955369
76. Santos R. A. S., Ferreira A. J., Simões E Silva A. C., Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Experimental Physiology 2008 93 5 519 527 2-s2.0-42649115768 10.1113/expphysiol.2008.042002 (Pubitemid 351595060)
77. Ferrarlo C. M., cferrari@wfubmc.edu ACE2: more of Ang-(1-7) or less Ang II? Current Opinion in Nephrology and Hypertension 2011 20 1 1 6 10.1097/MNH.0b013e3283406f57
78. Ocaranza M. P., mocaran@med.puc.cl Rivera P., Novoa U., Pinto M., González L., Chiong M., Lavandero S., Jalil J. E., jjalil@med.puc.cl Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1-9) axis in experimental hypertension. Journal of Hypertension 2011 29 4 706 715 10.1097/HJH.0b013e3283440665
79. Heeneman S., Sluimer J. C., Daemen M. J. A. P., Angiotensin-converting enzyme and vascular remodeling. Circulation Research 2007 101 5 441 454 2-s2.0-34548297520 10.1161/CIRCRESAHA.107.148338 (Pubitemid 47347875)
80. Hacking W. J. G., Vanbavel E., Spaan J. A. E., Shear stress is not sufficient to control growth of vascular networks: Aa model study. American Journal of Physiology 1996 270 1 H364 H375 2-s2.0-0030049024
81. Pasterkamp G., Galis Z. S., De Kleijn D. P. V., Expansive arterial remodeling: location, location, location. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 4 650 657 2-s2.0-1842475895 10.1161/01.ATV.0000120376. 09047.fe (Pubitemid 38451599)
82. Korner P. I., Angus J. A., Mulvany M. J., Vascular remodeling. Hypertension 1997 29 4 1065 1066 2-s2.0-0030989002 (Pubitemid 27152482)
83. De Mey J. G. R., Schiffers P. M., Hilgers R. H. P., Sanders M. M. W., Toward functional genomics of flow-induced outward remodeling of resistance arteries. American Journal of Physiology 2005 288 3 H1022 H1027 2-s2.0-13944254749 10.1152/ajpheart.00800.2004 (Pubitemid 40270002)
84. Iwai N., Izumi M., Inagami T., Kinoshita M., Induction of renin in medial smooth muscle cells by balloon injury. Hypertension 1997 29 4 1044 1050 2-s2.0-0030895230 (Pubitemid 27152479)
85. Rakugi H., Wang D. S., Dzau V. J., Pratt R. E., Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 1994 90 1 449 455 2-s2.0-0028272442 (Pubitemid 24203711)
86. Rizzoni D., Porteri E., Bettoni G., Piccoli A., Castellano M., Muiesan M. L., Pasini G., Guelfi D., Rosei E. A., Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology 1998 32 5 798 806 2-s2.0-0031734369 10.1097/00005344-199811000- 00017 (Pubitemid 28506652)
87. Rizzoni D., Porteri E., Piccoli A., Castellano M., Bettoni G., Muiesan M. L., Pasini G., Guelfi D., Mulvany M. J., Agabiti Rosei E., Effects of losartan and enalapril on small artery structure in hypertensive rats. Hypertension 1998 32 2 305 310 2-s2.0-0031843825 (Pubitemid 28376489)
88. Thybo N. K., Stephens N., Cooper A., Aalkjaer C., Heagerty A. M., Mulvany M. J., Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995 25 4 I 474 481 2-s2.0-0028929787
89. Schiffrin E. L., Park J. B., Intengan H. D., Touyz R. M., Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000 101 14 1653 1659 2-s2.0-0034636121 (Pubitemid 30196624)
90. Porteri E., Rizzoni D., Piccoli A., Castellano M., Bettoni G., Muiesan M. L., Pasini G., Guelfi D., Zulli R., Rosei E. A., Effects of hypotensive and non-hypotensive doses of manidipine on structure, responses to endothelin-1 and ICAM-1 production in mesenteric small resistance arteries of spontaneously hypertensive rats. Blood Pressure 1998 7 5-6 324 330 2-s2.0-0032443561 (Pubitemid 29182823)
91. Hamming I., Timens W., Bulthuis M. L. C., Lely A. T., Navis G. J., van Goor H., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. Journal of Pathology 2004 203 2 631 637 2-s2.0-2642539225 10.1002/path.1570 (Pubitemid 38714099)
92. Igase M., Strawn W. B., Gallagher P. E., Geary R. L., Ferrario C. M., Angiotensin II at1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. American Journal of Physiology 2005 289 3 H1013 H1019 2-s2.0-23944472129 10.1152/ajpheart.00068.2005 (Pubitemid 41208941)
93. Strawn W. B., Ferrario C. M., Tallant E. A., Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999 33 1 207 211 2-s2.0-0032898753 (Pubitemid 29065661)
94. Freeman E. J., Chisolm G. M., Ferrario C. M., Tallant E. A., Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996 28 1 104 108 2-s2.0-0029957780 (Pubitemid 26231097)
95. Igase M., Kohara K., Nagai T., Miki T., Ferrario C. M., Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertension Research 2008 31 3 553 559 2-s2.0-42649136964 10.1291/hypres.31.553 (Pubitemid 351597510)
96. Mogielnicki A., Chabielska E., Pawlak R., Szemraj J., Buczko W., Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thrombosis and Haemostasis 2005 93 6 1069 1076 2-s2.0-20444489976 10.1160/TH04-10-0701 (Pubitemid 40823510)
97. Kamiska M., Mogielnicki A., Stankiewicz A., Kramkowski K., Domaniewski T., Buczko W., Chabielska E., chabewa@nets.com.pl Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats. Journal of Physiology and Pharmacology 2005 56 4 571 585 (Pubitemid 43127554)
98. Kucharewicz I., Pawlak R., Matys T., Pawlak D., Buczko W., Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002 40 5 774 779 2-s2.0-0036841147 10.1161/01.HYP.0000035396.27909.40 (Pubitemid 35278618)
99. Kramkowski K., Mogielnicki A., Leszczynska A., Buczko W., Angiotensin-(1-9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats. Journal of Physiology and Pharmacology 2010 61 3 317 324 2-s2.0-77957074578
100. Rivera P., Ocaranza M. P., Lavandero S., Jalil J. E., Rho kinase activation and gene expression related to vascular remodeling in normotensive rats with high angiotensin I-converting enzyme levels. Hypertension 2007 50 4 792 798 2-s2.0-34548853983 10.1161/HYPERTENSIONAHA.107.095117 (Pubitemid 47442747)
101. Dzau V. J., VDZAU@partners.org Bernstein K., Celermajer D., Cohen J., Dahlöf B., Deanfield J., Diez J., Drexler H., Ferrari R., Van Gilst W., Hansson L., Hornig B., Husain A., Johnston C., Lazar H., Lonn E., Lüscher T., Mancini J., Mimran A., Pepine C., Rabelink T., Remme W., Ruilope L., Ruzicka M., Schunkert H., Swedberg K., Unger T., Vaughan D., Weber M., Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovascular Drugs and Therapy 2002 16 2 149 160 10.1023/A:1015709617405 (Pubitemid 34787797)
102. Silva D. M. R., Vianna H. R., Cortes S. F., Campagnole-Santos M. J., Santos R. A. S., Lemos V. S., Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides 2007 28 3 702 707 2-s2.0-33846799192 10.1016/j.peptides.2006.10.007 (Pubitemid 46204993)
103. Weiss D., Bernstein K. E., Fuchs S., Adams J., Synetos A., Taylor W. R., Vascular wall ACE is not required for atherogenesis in ApoE-/- mice. Atherosclerosis 2010 209 2 352 358 2-s2.0-77950022915 10.1016/j.atherosclerosis. 2009.09.069
104. Lee R. M. K. W., rmkwlee@mcmaster.ca Bader M., Alenina N., Santos R. A., Gao Y. J., Lu C., Mas receptors in modulating relaxation induced by perivascular adipose tissue. Life Sciences 2011 89 13-14 467 472 10.1016/j.lfs.2011.07.016
105. Lee R. M. K. W., Lu C., Su L. Y., Gao Y. J., Endothelium-dependent relaxation factor released by perivascular adipose tissue. Journal of Hypertension 2009 27 4 782 790 2-s2.0-67649663972 10.1097/HJH.0b013e328324ed86
106. Sampaio W. O., De Castro C. H., Santos R. A. S., Schiffrin E. L., Touyz R. M., Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007 50 6 1093 1098 2-s2.0-36448975192 10.1161/HYPERTENSIONAHA.106.084848 (Pubitemid 350172931)
107. Rabelo L. A., Alenina N., Bader M., mbader@mdc-berlin.de ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertension Research 2011 34 2 154 160 10.1038/hr.2010.235
108. Esteban V., Heringer-Walther S., Sterner-Kock A., de Bruin R., van den Engel S., Wang Y., Mezzano S., Egido J., Schultheiss H. P., Ruiz-Ortega M., Walther T., Angiotensin-(1-7) and the G protein-coupled receptor Mas are key players in renal inflammation. PLoS ONE 2009 4 4 2-s2.0-65549108738 10.1371/journal.pone.0005406 e5406
109. Velkoska E., Dean R. G., Griggs K., Burchill L., Burrell L. M., l.burrell@unimelb.edu.au Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clinical Science 2011 120 8 335 345 10.1042/CS20100280
110. Davies M. J., A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990 82 3 II38 II46 2-s2.0-15444364786
111. Opie L. H., Commerford P. J., Gersh B. J., Pfeffer M. A., Controversies in ventricular remodelling. The Lancet 2006 367 9507 356 367 2-s2.0-31444448021 10.1016/S0140-6736(06)68074-4 (Pubitemid 43151469)
112. Cohn J. N., Ferrari R., Sharpe N., Cardiac remodeling-concepts and clinical implications: a consensus paper from an International Forum on Cardiac Remodeling. Journal of the American College of Cardiology 2000 35 3 569 582 10.1016/S0735-1097(99)00630-0 (Pubitemid 30167013)
113. Gurley S. B., Allred A., Le T. H., Griffiths R., Mao L., Philip N., Haystead T. A., Donoghue M., Breitbart R. E., Acton S. L., Rockman H. A., Coffman T. M., Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. Journal of Clinical Investigation 2006 116 8 2218 2225 2-s2.0-33746724157 10.1172/JCI16980 (Pubitemid 44162331)
114. Huentelman M. J., Grobe J. L., Vazquez J., Stewart J. M., Mecca A. P., Katovich M. J., Ferrario C. M., Raizada M. K., Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Experimental Physiology 2005 90 5 783 790 2-s2.0-26044453206 10.1113/expphysiol.2005.031096 (Pubitemid 41406067)
115. Díez-Freire C., Vázquez J., Correa De Adjounian M. F., Ferrari M. F., Yuan L., Silver X., Torres R., Raizada M. K., mraizada@phys.med.ufl.edu ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiological Genomics 2006 27 1 12 19 10.1152/physiolgenomics.00312.2005 (Pubitemid 44511821)
116. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., Tatara Y., Shiota A., Sugano S., Takeda S., Rakugi H., Ogihara T., Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006 47 4 718 726 2-s2.0-33645834948 10.1161/01.HYP.0000205833.89478.5b (Pubitemid 43740244)
117. Grobe J. L., Mecca A. P., Lingis M., Shenoy V., Bolton T. A., Machado J. M., Speth R. C., Raizada M. K., Katovich M. J., Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). American Journal of Physiology 2007 292 2 H736 H742 2-s2.0-33846987938 10.1152/ajpheart.00937.2006